Interactive Drug Benefit List
DIN/NPN/PIN 02418320 LEMTRADA 12 MG / VIAL INJECTION ALEMTUZUMAB
100000 ANTINEOPLASTIC AGENTS
Date Listed/Coverage Update: 01-Sep-2016
Unit Price: 13,031.1100
LCA Price: N/A
MAC Price:

N/A

Unit of Issue: Vial
Manufacturer: GENZYME, A DIVISION OF SANOFI-AVENTIS CA (GZM)
ATC: L01XC04
1
Interchangeable Products: No

Coverage Status: SPECIAL AUTHORIZATION
Applies to Clients of: Non-Group Coverage (Group 1)
Coverage for Seniors (Group 66)
Palliative Coverage (Group 20514, Please note your client may have Group 1 or Group 66 coverage)
Child and Family Services (Group 20403)
Alberta Child Health Benefit (Group 20400)
Children and Youth Services (Group 19824)
Income Support (Group 19823)
Alberta Human Services (AISH) (Group 19823)
Alberta Adult Health Benefit (AAHB) (Group 23609)

Special Authorization Request Form:

Registration For MS Neurologist Status Form (ABC 60002)

Alemtuzumab for Multiple Sclerosis Special Authorization Request Form (ABC 60079)

Expand all Collapse all



"Special authorization coverage may be provided for the treatment of highly active relapsing remitting multiple sclerosis (RRMS) to reduce the frequency of clinical relapses, to decrease the number and volume of active brain lesions identified on magnetic resonance imaging (MRI) scans and to delay the progression of physical disability, in adult patients (18 years of age or older) who are refractory or intolerant to at least TWO of the following disease modifying therapies (DMTs):

- cladribine
- dimethyl fumarate
- fingolimod
- glatiramer acetate
- interferon beta
- natalizumab
- ocrelizumab
- ofatumumab
- peginterferon beta
- teriflunomide

Definition of 'intolerant'
Demonstrating serious adverse effects or contraindications to treatments as defined in the product monograph, or a persisting adverse event that is unresponsive to recommended management techniques and which is incompatible with further use of that class of MS disease modifying therapy (DMT).

Definition of 'refractory'
-Development of neutralizing antibodies to interferon beta.
-When the above MS DMTs are taken at the recommended doses for a full and adequate course of treatment, within a consecutive 12-month period while the patient was on the MS DMT, the patient has:
1) Been adherent to the MS DMT (greater than 80% of approved doses have been administered);
2) Experienced at least two relapses* of MS confirmed by the presence of neurologic deficits on examination.
i. The first qualifying clinical relapse must have begun at least one month after treatment initiation.
ii. Both qualifying relapses must be classified with a relapse severity of moderate, severe or very severe**.
*A relapse is defined as the appearance of new symptoms or worsening of old symptoms, lasting at least 48 hours in the absence of fever, not associated with withdrawal from steroids. Onset of clinical relapses must be separated by a period of at least one month. At least one new T2 lesion or definite gadolinium-enhancing T1 MRI lesion (not questionable faint enhancement) obtained at least 90 days after initiation of the DMT and at least 90 days before or after a relapse may substitute for one clinical relapse.
**Relapse severity: with moderate relapses modification or more time is required to carry out activities of daily living; with severe relapses there is inability to carry out some activities of daily living; with very severe relapses activities of daily living must be completed by others.
For coverage, this drug must be prescribed by a registered MS Neurologist. A current assessment must be completed by a registered MS Neurologist.
To register to become an MS Neurologist, please complete the Registration for MS Neurologist Status Form (ABC 60002).
Coverage may be considered only if the following criteria are met:
1) The registered MS Neurologist must confirm a diagnosis of RRMS;
2) The patient must have active disease which is defined as at least two relapses* of MS during the previous two years or in the two years prior to starting an MS DMT. In most cases this will be satisfied by the 'refractory' to treatment criterion but if a patient failed an MS DMT more than one year earlier, ongoing active disease must be confirmed.
3) The patient must be ambulatory with or without aid (The registered MS Neurologist must provide a current updated Expanded Disability Status Scale (EDSS) score less than or equal to 5).
Coverage will not be approved when any MS DMT or other immunosuppressive therapy is to be used in combination with alemtuzumab.

Coverage of alemtuzumab will not be approved if the patient was deemed to be refractory to alemtuzumab in the past.

Following assessment of the request, alemtuzumab may be approved for coverage at a dose of 12 mg/day administered by intravenous (IV) infusion for 2 treatment courses:
- Initial Treatment Course: 12 mg/day for 5 consecutive days (60 mg total dose)
- Second Treatment Course: 12 mg/day for 3 consecutive days (36 mg total dose) administered 12 months after the initial treatment course.

Patients will be limited to receiving one treatment course (60 mg or 36 mg) of alemtuzumab per prescription at their pharmacy.

Coverage is limited to two treatment courses (i.e., eight doses)."

All requests for alemtuzumab must be completed using the Alemtuzumab For Multiple Sclerosis Special Authorization Request Form (ABC 60079).

Review Status / Past Decisions

Indication Reviewing
Body
Submission
Completion
Date
CDR
Recommendation
Date
Expert Committee
Recommendation
Date
ADBL
Effective
Date
CDR
Recommendation
Review
Status
N/A Expert Committee 2023/07/20 2023/10/01 No Special Authorization Criteria Change
N/A Expert Committee 2022/06/01 2022/06/01 Special Authorization Criteria Change
MULTIPLE SCLEROSIS (RELAPSING-REMITTING) Expert Committee 2019/11/22 2020/06/01 Special Authorization Criteria Change (RRMS)
MULTIPLE SCLEROSIS (RELAPSING-REMITTING) Common Drug Review 2014/12/11 2015/11/01 Under Review
MULTIPLE SCLEROSIS (RELAPSING-REMITTING) Common Drug Review 2014/12/11 2016/05/01 Under Review
MULTIPLE SCLEROSIS (RELAPSING-REMITTING) Common Drug Review 2014/12/11 2016/03/01 Under Review
MULTIPLE SCLEROSIS (RELAPSING-REMITTING) Common Drug Review 2014/12/11 2016/09/01 Special Authorization
MULTIPLE SCLEROSIS (RELAPSING-REMITTING) Common Drug Review 2014/12/11 2015/06/18 View CDR - List with criteria/condition
MULTIPLE SCLEROSIS (RELAPSING-REMITTING) Common Drug Review 2014/12/11 2018/08/01 Special Authorization Criteria Change
Indication N/A
Reviewing
Body
Expert Committee
Submission
Completion
Date
2023/07/20
CDR
Recommendation
Date
Expert Committee
Recommendation
Date
ADBL
Effective
Date
2023/10/01
CDR
Recommendation
Review
Status
No Special Authorization Criteria Change
Indication N/A
Reviewing
Body
Expert Committee
Submission
Completion
Date
2022/06/01
CDR
Recommendation
Date
Expert Committee
Recommendation
Date
ADBL
Effective
Date
2022/06/01
CDR
Recommendation
Review
Status
Special Authorization Criteria Change
Indication MULTIPLE SCLEROSIS (RELAPSING-REMITTING)
Reviewing
Body
Expert Committee
Submission
Completion
Date
2019/11/22
CDR
Recommendation
Date
Expert Committee
Recommendation
Date
ADBL
Effective
Date
2020/06/01
CDR
Recommendation
Review
Status
Special Authorization Criteria Change (RRMS)
Indication MULTIPLE SCLEROSIS (RELAPSING-REMITTING)
Reviewing
Body
Common Drug Review
Submission
Completion
Date
2014/12/11
CDR
Recommendation
Date
Expert Committee
Recommendation
Date
ADBL
Effective
Date
2015/11/01
CDR
Recommendation
Review
Status
Under Review
Indication MULTIPLE SCLEROSIS (RELAPSING-REMITTING)
Reviewing
Body
Common Drug Review
Submission
Completion
Date
2014/12/11
CDR
Recommendation
Date
Expert Committee
Recommendation
Date
ADBL
Effective
Date
2016/05/01
CDR
Recommendation
Review
Status
Under Review
Indication MULTIPLE SCLEROSIS (RELAPSING-REMITTING)
Reviewing
Body
Common Drug Review
Submission
Completion
Date
2014/12/11
CDR
Recommendation
Date
Expert Committee
Recommendation
Date
ADBL
Effective
Date
2016/03/01
CDR
Recommendation
Review
Status
Under Review
Indication MULTIPLE SCLEROSIS (RELAPSING-REMITTING)
Reviewing
Body
Common Drug Review
Submission
Completion
Date
2014/12/11
CDR
Recommendation
Date
Expert Committee
Recommendation
Date
ADBL
Effective
Date
2016/09/01
CDR
Recommendation
Review
Status
Special Authorization
Indication MULTIPLE SCLEROSIS (RELAPSING-REMITTING)
Reviewing
Body
Common Drug Review
Submission
Completion
Date
2014/12/11
CDR
Recommendation
Date
2015/06/18
Expert Committee
Recommendation
Date
ADBL
Effective
Date
CDR
Recommendation
View
Review
Status
CDR - List with criteria/condition
Indication MULTIPLE SCLEROSIS (RELAPSING-REMITTING)
Reviewing
Body
Common Drug Review
Submission
Completion
Date
2014/12/11
CDR
Recommendation
Date
Expert Committee
Recommendation
Date
ADBL
Effective
Date
2018/08/01
CDR
Recommendation
Review
Status
Special Authorization Criteria Change
To return to the printable Drug Benefit List and related publications, click here
Last Updated:
NOTICE:
The DBL, DBS and related publications require knowledgeable interpretation and are intended primarily for professional health care practitioners, pharmacies, hospitals and organizations associated with the manufacture, distribution and use of pharmaceutical preparations.
Electronic versions of all DBL and DBS related publications are unofficial versions and are provided for convenience and private use only. Official paper versions can be obtained from Alberta Blue Cross who publishes them on behalf of Alberta Health and Alberta Human Services.
Alberta Health reserves the right to make changes, without notice, to the List through the Interactive DBL(iDBL), and any such changes to the Interactive DBL(iDBL) are effective the date of the change (unless otherwise stated) and regardless of the date of publication in the paper version or updates.